Disclosed are methods for treating a subject having or at risk of developing a disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath, by administering an effective amount of sobetirome or a sobetirome prodrug and one or more PPAR activators to the subject. Also disclosed are pharmaceutical compositions in unit dosage form containing an effective amount of sobetirome or a sobetirome prodrug, one or more PPAR activators, and a pharmaceutically acceptable excipient.
